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Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease characterized by formation of a 
variety of autoantibodies and development of skin rash and internal involvements such as glomerulonephritis. 
Although the underlying etiology still remains unknown, the genetic predisposition and environmental factors 
together contribute to the initiation of SLE. It has been thought that aberration of adaptive immunity associated 
with immunological tolerance and resulting B cell hyperactivation leads to production of autoantibodies against 
chromatin and ribonucleoproteins. In contrast, recent studies have demonstrated that innate immunity including 
TLR signaling plays an essential role in the development of SLE. Previous studies demonstrated that disease in 
lupus-prone mice was dependent on the presence of TLR7, and that treatment of them with a TLR7 agonist 
aggravated lupus nephritis. Here we report that repeated topical treatment of wild-type mice with a TLR7 agonist 
imiquimod (IMQ) resulted in generation of autoantibodies and glomerulonephritis. Wild-type mice of FVB/N 
strain, regardless of sex, which were topically applied by IMQ onto the ear pinna three times weekly, showed 
anti-double strand DNA antibodies in the sera from 4 weeks, increased creatinine levels, and glomerulonephritis 
by 8 weeks, and finally died by 10 weeks of the treatment. Direct immunofluorecence examination of the 
glomeruli revealed deposits of IgG and IgM autoantibodies. Wild-type mice from other strains including 
C57BL/6 and BALB/c also developed autoantibodies and glomerulonephritis following epicutaneous IMQ 
treatment, suggesting that repeated TLR7 stimulation via skin lead to lupus-like disease in wild-type mice beyond 
the genetic background. Collectively, these results suggested that cutaneous perturbation by TLR7 agonists such 
as RNA viruses might be implicated in the onset of SLE. 
